Mycobacterium tuberculosis

From IDWiki
Mycobacterium tuberculosis /
Revision as of 18:13, 9 October 2019 by Aidan (talk | contribs) ()
  • Mycobacterium tuberculosis causes tuberculosis
  • Most commonly pulmonary TB but extrapulmonary tuberculosis is possible (including adenitis, gastrointestinal TB, pericarditis, meningitis)
  • Standard treatment for susceptible TB is RIPE x2mo then RI x4mo

Classification

  • Primary vs. reactivation vs. reinfection
  • Latent vs. active

Epidemiology

  • Reinfection accounts for ~40% of active tuberculosis in endemic countries
  • Latent tuberculosis in ~30% of the global population

Clinical Presentation

Primary tuberculosis

  • Primary tuberculosis is usually asymptomatic
  • Possible presentations include mild URTI with cough and/or fever
  • May be seen on CXR as infiltrate in mid-lung zones with hilar adenopathy
  • Ghon complex, especially in children
  • May progress in children and the immunocompromised patients
  • Immunological phenomena
    • Erythema nodosum
    • Phlyctenular conjunctivitis
    • Erythema induratum

Pulmonary tuberculosis

  • Subacute or chronic cough (at least 2 to 3 weeks) eventually becoming productive and occasionally involving hemoptysis
    • Should be suspected in any patient with cough and HIV infection
  • Constitutional symptoms, with fevers, night sweats, and unexplained weight loss
  • Usually from reactivation of latent tuberculosis infection, and usually reactivates in lung apices
  • May transiently improve with partially-active antibiotics such as fluoroquinolones

Extra-pulmonary tuberculosis

Latent tuberculosis

Investigations

  • AM sputum for acid-fast bacilli x3
    • About 70% sensitive
  • ANTB (PCR)
    • About 75% sensitive

Management

  • Standard HREZ x2mo then HR x4mo
    • Isoniazid 5mg/kg/d, max 300mg daily
    • Rifampin 10mg/kg/d
    • Pyrazinamide 25mg/kg/d, max 2g daily
    • Ethambutol 20mg/kg/d, max 1.2g daily
    • Pyridoxine
  • Airborne precautions until:
    • Treated for at least 2 weeks
    • 3x negative sputum smears
      • Collected at 8- to 24-hour intervals, including one early morning collection
    • Improvement in symptoms

IRIS

DILI

  • Most common complication leading to treatment interruption, with a mortality of 6-12% if drugs are not stopped
  • Rif > INH > PZA
  • Most patients can have the same TB drugs reintroduced without recurrence of DILI, though recurrence can be delayed
  • Procedure
    • Hold if ALT >120 and symptoms, if ALT >200 even without symptoms, or bili >2x ULN
    • Switch to second-line meds
    • Reintroduce the original drugs once AST & ALT are <2x ULN
    • Only rechallenge with pyrazinamide if it was a mild case

Adherence to Treatment

Further Reading

References

  1. ^  Daphne Yee, Chantal Valiquette, Marthe Pelletier, Isabelle Parisien, Isabelle Rocher, Dick Menzies. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2003;167(11):1472-1477. doi:10.1164/rccm.200206-626oc.
  2. ^  Jussi J. Saukkonen, David L. Cohn, Robert M. Jasmer, Steven Schenker, John A. Jereb, Charles M. Nolan, Charles A. Peloquin, Fred M. Gordin, David Nunes, Dorothy B. Strader, John Bernardo, Raman Venkataramanan, Timothy R. Sterling. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. American Journal of Respiratory and Critical Care Medicine. 2006;174(8):935-952. doi:10.1164/rccm.200510-1666st.